Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study - Papp, K.A.; Kaufmann, R.; Thaçi, D.; Hu, C.; Sutherland, D.; Rohane, P. (Journal of the European Academy of Dermatology and Venereology, 2013)
Keywords: Alcoholism; Anti-Inflammatory Agents, Non-Steroidal - adverse effects; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Anxiety; BID protein; Diarrhea; Double-Blind Method; Drug abuse; Headache; Humans; Inflammation; Knee; Nausea; Opportunist infection; phosphodiesterase IV; Placebos; Plaques; Psoriasis; Psoriasis - drug therapy; Rehabilitation; Rhinopharyngitis; Severity of Illness Index; Surface area; Surgery; Thalidomide - adverse effects; Thalidomide - analogs & derivatives; Thalidomide - therapeutic use